Genomic Health (GHDX) Appoints New CEO and COO
More News related to GHDX
- Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
- Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
- Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
- Oncotype DX(R) Guides Individualized Treatment Decisions for More Than 100,000 Breast Cancer Patients Worldwide
- Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting
Genomic Health, Inc. (Nasdaq: GHDX) today announced the appointment of Kimberly Popovits as CEO. In addition, G. Bradley Cole has been appointed as COO and will continue to serve as the company's CFO, reporting to Popovits.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer that enable physicians and patients to make individualized treatment decisions in the United States.
Related Categories
Management ChangesStocks Mentioned
-0.82Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
